Ipsen (GB:0MH6) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Ipsen is conducting a study titled A Prospective Real-World Study Evaluating Objective Response Rate and Duration of Response of Tazemetostat Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Following at Least Two Prior Lines of Treatment. The study aims to assess the effectiveness and safety of Tazemetostat in adults with relapsed or refractory follicular lymphoma, a type of blood cancer affecting lymphocytes, after they have undergone at least two previous therapies.
Intervention/Treatment: The study focuses on Tazemetostat, an oral medication administered at 800 mg twice daily. It is designed to treat follicular lymphoma by targeting specific cancer cells, with treatment continuing until disease progression or unacceptable side effects occur.
Study Design: This observational study follows a cohort model with a prospective time perspective. Participants will receive Tazemetostat as part of their routine clinical care, and the study will monitor treatment response, duration, and safety.
Study Timeline: The study is not yet recruiting, with the initial submission on November 27, 2025, and the latest update on December 12, 2025. These dates indicate the study’s early planning stages, with recruitment and data collection yet to commence.
Market Implications: The study’s progress could influence Ipsen’s stock performance and investor sentiment, particularly if Tazemetostat demonstrates significant efficacy and safety. This could position Ipsen favorably against competitors in the oncology sector, potentially boosting its market share and investor confidence.
The study is ongoing, with further details available on the ClinicalTrials portal.
To learn more about GB:0MH6’s potential, visit the Ipsen drug pipeline page.